dimecres, 6 d’agost del 2014

SonaCare lands a date with the FDA for prostate cancer therapy




Ablation devices maker SonaCare Medical lands a meeting to review its ultrasound-based prostate cancer ablation device with an FDA panel that just shot down similar device.





SonaCare lands a date with the FDA for prostate cancer therapy

North Carolina-based SonaCare Medical is getting a day with the FDA, but the company's prospects are murky given that it's going before an advisory panel that just rejected a technology similar to SonaCare's Sonablate 450 prostate cancer therapy.




read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/XExCH1

Cap comentari:

Publica un comentari a l'entrada